In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Participants will get treatment right up until disorder progression or maybe the contributors are not able to tolerate the study drugs. Doable new approaches to the analysis and treatment of AML. https://abbv-744-in-the-treatment46891.bloggactif.com/33011021/5-essential-elements-for-abbv-744-drug-development-progress-and-timeline